Lates News

According to the AI Flash News of Meijing, Guojin Securities released a research report on December 3, giving a "buy" rating to Sansheng Guojian (688336.SH). The rating reasons include: 1) Deeply layout the self-immunity track, the stock variety will contribute stable income in the short term; 2) All four core pipeline projects have entered the late clinical stage, with a peak contribution expected to exceed 5.5 billion yuan in the future; 3) Early research pipeline tracks are of high quality and have the potential to become new generation targets; 4) All tumor lines have been authorized by Sansheng Pharmaceutical, the first payment of 707 bispecific antibodies may be confirmed and contribute to revenue of 2.6 billion yuan in 2025, significantly increasing that year's performance. (Daily Economic News)